Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB1 receptors in rodents.

Terry G, Liow JS, Chernet E, Zoghbi SS, Phebus L, Felder CC, Tauscher J, Schaus JM, Pike VW, Halldin C, Innis RB.

Neuroimage. 2008 Jul 1;41(3):690-8. doi: 10.1016/j.neuroimage.2008.03.004. Epub 2008 Mar 18.

2.

The PET radioligand [11C]MePPEP binds reversibly and with high specific signal to cannabinoid CB1 receptors in nonhuman primate brain.

Yasuno F, Brown AK, Zoghbi SS, Krushinski JH, Chernet E, Tauscher J, Schaus JM, Phebus LA, Chesterfield AK, Felder CC, Gladding RL, Hong J, Halldin C, Pike VW, Innis RB.

Neuropsychopharmacology. 2008 Jan;33(2):259-69. Epub 2007 Mar 28.

3.

Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand.

Terry GE, Liow JS, Zoghbi SS, Hirvonen J, Farris AG, Lerner A, Tauscher JT, Schaus JM, Phebus L, Felder CC, Morse CL, Hong JS, Pike VW, Halldin C, Innis RB.

Neuroimage. 2009 Nov 1;48(2):362-70. doi: 10.1016/j.neuroimage.2009.06.059. Epub 2009 Jun 30.

4.

Imaging and quantitation of cannabinoid CB1 receptors in human and monkey brains using (18)F-labeled inverse agonist radioligands.

Terry GE, Hirvonen J, Liow JS, Zoghbi SS, Gladding R, Tauscher JT, Schaus JM, Phebus L, Felder CC, Morse CL, Donohue SR, Pike VW, Halldin C, Innis RB.

J Nucl Med. 2010 Jan;51(1):112-20. doi: 10.2967/jnumed.109.067074. Epub 2009 Dec 15.

5.

Pharmacological characterization of the cannabinoid CB₁ receptor PET ligand ortholog, [³H]MePPEP.

Suter TM, Chesterfield AK, Bao C, Schaus JM, Krushinski JH, Statnick MA, Felder CC.

Eur J Pharmacol. 2010 Dec 15;649(1-3):44-50. doi: 10.1016/j.ejphar.2010.08.055. Epub 2010 Sep 17.

PMID:
20851117
6.

Evaluation of [11C]PipISB and [18F]PipISB in monkey as candidate radioligands for imaging brain cannabinoid type-1 receptors in vivo.

Finnema SJ, Donohue SR, Zoghbi SS, Brown AK, Gulyás B, Innis RB, Halldin C, Pike VW.

Synapse. 2009 Jan;63(1):22-30. doi: 10.1002/syn.20578.

7.

Endocannabinoids potently protect the newborn brain against AMPA-kainate receptor-mediated excitotoxic damage.

Shouman B, Fontaine RH, Baud O, Schwendimann L, Keller M, Spedding M, Lelièvre V, Gressens P.

Br J Pharmacol. 2006 Jun;148(4):442-51. Epub 2006 May 8.

8.

In vitro and in vivo evaluation of (11)C-SD5024, a novel PET radioligand for human brain imaging of cannabinoid CB1 receptors.

Tsujikawa T, Zoghbi SS, Hong J, Donohue SR, Jenko KJ, Gladding RL, Halldin C, Pike VW, Innis RB, Fujita M.

Neuroimage. 2014 Jan 1;84:733-41. doi: 10.1016/j.neuroimage.2013.09.043. Epub 2013 Sep 25.

9.

Biodistribution and dosimetry in humans of two inverse agonists to image cannabinoid CB1 receptors using positron emission tomography.

Terry GE, Hirvonen J, Liow JS, Seneca N, Tauscher JT, Schaus JM, Phebus L, Felder CC, Morse CL, Pike VW, Halldin C, Innis RB.

Eur J Nucl Med Mol Imaging. 2010 Aug;37(8):1499-506. doi: 10.1007/s00259-010-1411-7. Epub 2010 Mar 24.

10.

Test-retest reproducibility of cannabinoid-receptor type 1 availability quantified with the PET ligand [¹¹C]MePPEP.

Riaño Barros DA, McGinnity CJ, Rosso L, Heckemann RA, Howes OD, Brooks DJ, Duncan JS, Turkheimer FE, Koepp MJ, Hammers A.

Neuroimage. 2014 Aug 15;97:151-62. doi: 10.1016/j.neuroimage.2014.04.020. Epub 2014 Apr 13.

11.

11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors.

Horti AG, Fan H, Kuwabara H, Hilton J, Ravert HT, Holt DP, Alexander M, Kumar A, Rahmim A, Scheffel U, Wong DF, Dannals RF.

J Nucl Med. 2006 Oct;47(10):1689-96.

12.

Inhibitory CB1 and activating/desensitizing TRPV1-mediated cannabinoid actions on CGRP release in rodent skin.

Engel MA, Izydorczyk I, Mueller-Tribbensee SM, Becker C, Neurath MF, Reeh PW.

Neuropeptides. 2011 Jun;45(3):229-37. doi: 10.1016/j.npep.2011.03.005. Epub 2011 Apr 22.

PMID:
21514666
13.

Dysregulation of the endogenous cannabinoid system in adult rats prenatally treated with the cannabinoid agonist WIN 55,212-2.

Castelli MP, Paola Piras A, D'Agostino A, Pibiri F, Perra S, Gessa GL, Maccarrone M, Pistis M.

Eur J Pharmacol. 2007 Nov 14;573(1-3):11-9. Epub 2007 Jul 4.

PMID:
17644084
14.

Anandamide inhibits transport-related oxygen consumption in the loop of Henle by activating CB1 receptors.

Silva GB, Atchison DK, Juncos LI, García NH.

Am J Physiol Renal Physiol. 2013 Feb 15;304(4):F376-81. doi: 10.1152/ajprenal.00239.2012. Epub 2012 Dec 5.

15.

Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: a PET study.

Takano A, Gulyás B, Varnäs K, Little PB, Noerregaard PK, Jensen NO, Elling CE, Halldin C.

Synapse. 2014 Mar;68(3):89-97. doi: 10.1002/syn.21721. Epub 2013 Dec 2.

PMID:
24293119
16.

In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569.

Gamage TF, Ignatowska-Jankowska BM, Wiley JL, Abdelrahman M, Trembleau L, Greig IR, Thakur GA, Tichkule R, Poklis J, Ross RA, Pertwee RG, Lichtman AH.

Behav Pharmacol. 2014 Apr;25(2):182-5. doi: 10.1097/FBP.0000000000000027.

17.
18.

Anandamide-mediated CB1/CB2 cannabinoid receptor--independent nitric oxide production in rabbit aortic endothelial cells.

McCollum L, Howlett AC, Mukhopadhyay S.

J Pharmacol Exp Ther. 2007 Jun;321(3):930-7. Epub 2007 Mar 22.

19.

Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase.

Haller VL, Stevens DL, Welch SP.

Eur J Pharmacol. 2008 Dec 14;600(1-3):50-8. doi: 10.1016/j.ejphar.2008.08.005. Epub 2008 Aug 20.

PMID:
18762181
20.

Inhibition of fatty acid amide hydrolase unmasks CB1 receptor and TRPV1 channel-mediated modulation of glutamatergic synaptic transmission in midbrain periaqueductal grey.

Kawahara H, Drew GM, Christie MJ, Vaughan CW.

Br J Pharmacol. 2011 Jul;163(6):1214-22. doi: 10.1111/j.1476-5381.2010.01157.x.

Supplemental Content

Support Center